Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy

Journal of Cardiovascular Electrophysiology

Volumn 19, Issue 10, 2008, Pages 1118-1126

  Maron, Barry J ^a   Spirito, Paolo ^b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

Cardiomyopathy; Defibrillator; Hypertrophy; Sudden death

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; VERAPAMIL;

CARDIOVASCULAR RISK; CULTURAL FACTOR; DEFIBRILLATOR; DISEASE ASSOCIATION; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN DEATH; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

CARDIOMYOPATHY, HYPERTROPHIC; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 52149115094     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2008.01147.x     Document Type: Review

References (89)

1. Teare D : Asymmetrical hypertrophy of the heart in young athletes. Br Heart J 1958 20 : 1 8.
2. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, ten Cate FJ, Wigle ED : American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003 42 : 1687 1713.
3. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr., Morrow AG : Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. Circulation 1964 30 (Suppl. IV IV-3 IV-119.
4. Maron BJ : Hypertrophic cardiomyopathy: A systematic review. JAMA 2002 187 : 1308 1320.
5. Spirito P, Seidman CE, McKenna WJ, Maron BJ : The management of hypertrophic cardiomyopathy. N Engl J Med 1997 336 : 775 785.
6. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ : Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000 342 : 1778 1785.
7. Maron BJ : Sudden death in young athletes. N Engl J Med 2003 349 : 1064 1075.
8. Elliott PM, Gimeno B Jr., Mahon NG, Poloniecki JD, McKenna WJ : Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001 357 : 420 424.
9. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ : Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000 36 : 2212 2218.
10. Maron BJ, Shen W-K, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NAM III., Casey SA, Stanton MS, Betocchi S, Spirito P : Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000 342 : 365 373.
11. Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NAM III., Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P : Outcomes of patients with implantable cardioverter-defibrillators for prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007 298 : 405 412.
12. Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richmond DR, Semsarian C : Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004 93 : 1192 1194.
13. Woo A, Monakier D, Harris L, Shah P, Wigle ED, Rakowski H, Rozenblyum E, Cameron DA : Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007 93 : 1044 1045.
14. Cha Y-M, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen W-K : Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2007 18 : 1 5.
15. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ : Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999 33 : 1596 1601.
16. Marin F, Gimeno JR, Payá E, Garcia-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martinez JG, Monserrat L : Implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers. Rev Esp Cardiol 2006 59 : 537 544.
17. Przybylski A, Matecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciǎg A, Rużytto W, Szwed H : Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy - Dilemmas and difficulties. Kardiol Pol 2005 63 : 391 397.
18. Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Nevas JP, Bonhosrst D, Gomes JL, Gomes RS : Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy. Rev Port Cardiol 2005 24 : 407 415.
19. Klein GJ, Krahn AD, Skanes AC, Yee R, Gula LJ : Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy. J Cardiovasc Electrophysiol 2005 16 : S28 S34.
20. Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, Valentino M, Brugada P : Hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998 31 : 1081 1085.
21. Kaski JP, Esteban MTT, Lowe M, Sporton S, Rees P, Deanfield JE, McKenna WJ, Elliott PM : Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007 93 : 372 374.
22. Almquist AK, Montgomery JV, Haas TS, Maron BJ : Cardioverter- defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm 2005 2 : 814 819.
23. Boriani G, Maron BJ, Shen W-K, Spirito P : Prevention of sudden death in hypertrophic cardiomyopathy: But which defibrillator for which patient? Circulation 2004 110 : e438 e442.
24. Maron BJ, Estes NAM III., Maron MS, Almquist AK, Link MS, Udelson J : Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003 107 : 2872 2875.
25. Stephenson EA, Berul CI : Electrophysiological interventions for inherited arrhythmia syndromes. Circulation 2007 116 : 1062 1080.
26. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik SA, Fischell RE, Weisfeldt ML : Termination of malignant ventricular arrhythmias with an implantable automatic defibrillator in human beings. N Engl J Med 1980 303 : 322 324.
27. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators : A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997 337 : 1576 1583.
28. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 335 : 1933 1940.
29. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber D, Cannom D, Daubert J, Higgins S, Brown M, Andrews M for the MADIT II Investigators : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 346 : 877 883.
30. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 : 225 237.
31. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G, for the Multicenter Unsustained Tachycardia Trial Investigators : A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999 341 : 1882 1890.
32. Desai AS, Fang JC, Maisel WH, Baughman KL : Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy. A meta-analysis of randomized controlled trials. JAMA 2004 292 : 2874 2879.
33. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators : Prophylactic defibrillator implantation in patients with non-ischemic dilated cardiomyopathy. N Engl J Med 2004 350 : 2151 2158.
34. Cesario DA, Dec GW : Implantable cardioverter-defibrillator therapy in clinical practice. J Am Coll Cardiol 2006 47 : 1507 1517.
35. Josephson M, Wellens HJJ : Implantable defibrillators and sudden cardiac death. Circulation 2004 109 : 2685 2691.
36. Passman R, Kadish A : Sudden death prevention with implantable devices. Circulation 2007 116 : 561 571.
37. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF : Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1984 53 : 412 416.
38. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, Thiene G, Iliceto S : Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007 93 : 708 710.
39. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L : Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003 26 : 1887 1896.
40. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd., Buja G, Thiene G : Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003 108 : 3084 3091.
41. Sacher F, Probst V, Iesaka Y, Jacon P, Labordeire J, Mizon-Gérard F, Mabo P, Reuter S, Lamaison D, Takahashi Y, O'Neill MD, Garrigue S, Pierre B, Jaïs P, Pasquié J-L, Hocini M, Salvador-Mazenq M, Nogami A, Amiel A, Defaye P, Bordachar P, Boveda S, Maury P, Klug D, Babuty D, Haïssaguerre M, Mansourati J, Clémenty J, Le Marec H : Outcome after implantation of a cardioverter-defibrillator in patients with Brugada Syndrome. A multicenter study. Circulation 2006 114 : 2317 2324.
42. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson MS, Andrews M : Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003 14 : 337 341.
43. Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, Rutberg J, Crosson J, Spevak PJ, Berger RD, Halperin HR, Calkins H : Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2004 43 : 1843 1852.
44. Sarkozy A, Boussy T, Kourgiannides G, Chierchia G-B, Richter S, De Potter T, Geelen P, Wellens F, Spreeuwenberg MD, Brugada P : Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007 28 : 334 344.
45. Wichter T, Paul M, Wollman C, Acil T, Gerdes P, Ashraf O, Tjan TDT, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Böcker D : Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy. Single-center experience of long-term follow-up and complications in 60 patients. Circulation 2004 109 : 1503 1508.
46. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, Sitthisook S, Chaothawee L, Lai MY, Azen SP : Defibrillator versus β-blockers for unexplained death in Thailand (DEBUT). A randomized clinical trial. Circulation 2003 107 : 2221 2226.
47. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg MJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C : ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). Circulation 2006 114 : e385-e484.
48. Monserrat L, Elliott PM, Gimeno JR, McKenna WJ. Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003 42 : 873 879.
49. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999 33 : 2044 2051.
50. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005 45 : 697 704.
51. Elliott P, McKenna WJ : Hypertrophic cardiomyopathy. Lancet 2004 363 : 1881 1891.
52. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CT, Appelbaum E, Main ML, Roberts WC. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008 : 101 : 544 547.
53. Maron MS, Appelbaum E, Harrigan C, Buros J, Gibson C, Hannah C, Lesser LR, Udelson JE, Manning WJ, Maron BJ. Significance of delayed enhancement with contrast enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy (abstract). Circulation 2007 116 (Suppl. II II 694.
54. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ : Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006 114 : 216 225.
55. Maron MS, Bos JM, Ackerman MJ, Lesser JR, Finley JJ, Udelson JE, Zenovich AG, Manning WJ, Maron BJ : Left ventricular apical aneurysms: A novel under-recognized subgroup within the hypertrophic cardiomyopathy disease spectrum (abstract). Circulation 2006 114 (Suppl. III II-439.
56. Kimmelstiel CD, Maron BJ : Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004 109 : 452 456.
57. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ : Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007 49 : 350 357.
58. Maron BJ : Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007 116 : 196 206.
59. Watkins H, Rosenzweig A, Hwang D-S, Levi T, McKenna W, Seidman CE, Seidman JG : Characteristics and prognostic implications of myosin missense mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. N Engl J Med 1992 326 : 1108 1114.
60. Seidman JG, Seidman CE : The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 2001 104 : 557 567.
61. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman R, Siscovick D, Stevenson WG, Zipes DP : AHA scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. Circulation, in press.
62. Maron BJ, Leyhe MJ III., Casey SA, Gohman TE, Lawler CM, Crow RS, Maron MS, Hodges M : Assessment of QT dispersion as a prognostic marker for sudden death in a regional non-referred, hypertrophic cardiomyopathy cohort : Am J Cardiol 2001 87 : 114 115.
63. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM : Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999 281 650 655.
64. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ : Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003 348 : 295 303.
65. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ : Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006 114 : 2232 2239.
66. Hauser RG, Maron BJ : Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation 2005 112 : 2040 2042.
67. Gornick CC, Hauser RG, Almquist AK, Maron BJ : Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. Heart Rhythm 2005 2 : 681 683.
68. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W : Cost effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvas Electrocardiol 2005 10 (Suppl. 4 67 83.
69. Maron BJ, Haas TS : Unanticipated long-term survival after cardiac arrest in hypertrophic cardiomyopathy (abstract) : Circulation 2007 116 (Suppl. II II 766.
70. Almquist AK, Hanna CA, Haas TS, Maron BJ : Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008 19 : 319 322.
71. Germano JJ, Reynolds M, Essebag V, Josephson ME : Frequency and causes of implantable cardioverter-defibrillator therapies: Is device therapy proarrhythmic? Am J Cardiol 2006 97 : 1255 1261.
72. Silka MJ, Kron J, Dunnigan A, Dick M II. for the Pediatric Electrophysiology Society : Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 1993 87 : 800 807.
73. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TG, Graham KJ, Burton DA, Cecchi F : Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patient population. Circulation 2000 102 : 858 864.
74. Link MS, Hill SL, Cliff DL, Swygman CA, Estes NAM III., Berul CI : Comparison of frequency of complications of implantable cardioverter- defibrillators in children versus adults. Am J Cardiol 1999 83 : 263 266.
75. Hamilton RM, Dorian P, Gow RM, Williams WG : Five-year experience with implantable defibrillator in children. Am J Cardiol 1996 77 : 524 526.
76. Korte T, Köditz H, Niehaus M, Paul T, Tebbenjohanns J : High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004 27 : 924 932.
77. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI : Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol 2004 15 : 72 76.
78. Eicken A, Kolb C, Lange S, Brodherr-Heberlein S, Zrenner B, Schreiber C, Hess J : Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol 2006 107 : 30 35.
79. Camm A, Nisam S : The utilization of the implantable defibrillator - A European enigma. Eur Heart J 2000 21 : 1998 2004.
80. Kleeman T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, Weisse U, Seidl K : Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation 2007 115 : 2474 2480.
81. Wilkoff BL : How to treat and identify device infections. Heart Rhythm 2007 4 : 1467 1470.
82. Wilkoff BL : Lead failures: Dealing with even less perfect. Heart Rhythm 2007 7 : 897 899.
83. Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT : Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 2007 4 : 892 896.
84. Maisel WH : Transvenous implantable cardioverter-defibrillator leads. The weakest link. Circulation 2007 115 : 2461 2463.
85. Swerdlow CD : Small-diameter defibrillation electrodes: Can they take a licking and keep hearts ticking? Heart Rhythm 2007 4 : 898 899.
86. Hauser RG, Maron BJ : Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation 2007 112 : 2040 2042.
87. Maron BJ, Hauser RG : Past and future perspectives on the failure of pharmaceutical and medical device industries to protect the public health interests. Am J Cardiol 2007 100 : 147 141.
88. DeMaso DR, Lauretti A, Spieth L, Van Der Feen JR, Lay KS, Gauvreau K, Walsh EP, Berul CI : Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. Am J Cardiol 2004 93 : 582 587.
89. Sears SF, Conti JB : Psychosocial aspects of cardiac devices and recalls in implantable cardioverter defibrillators (editorial). Am J Cardiol 2006 98 : 565 567.